Surface modification method of implant and modified implant
By modifying the implant surface, the problem of slow ossembly binding and high infection risk of implants is solved by using live cells and growth factors in the plasma matrix, and faster ossembly binding and higher antibacterial performance are achieved.
Patent Information
- Application Number
- CN202311621290.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-11-28
- Publication Date
- 2025-07-08
AI Technical Summary
The bone binding time is long during implant implantation and is prone to infection. The existing surface modification methods have high prices, difficulty in storage and possible antigenicity.
The implant surface is modified by plasma matrix, and the living cells, growth factors and antibacterial peptides in the autologous blood are used to improve biocompatibility and antibacteriality and promote bone binding.
Accelerate implant bone binding, reduce the risk of infection, improve the long-term survival rate and antibacterial performance of the implant, and reduce rejection reactions.
Smart Images
Figure CN120267897A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of dental implants, and particularly to a surface modification method for implants and modified implants. Background Art
[0002] With the development of implant technology, implant placement has become one of the important means to solve dentition defect clinically at present. However, the osseointegration of implants usually takes 3 - 6 months, which usually makes patients wait for a long time, prolongs the toothless time, and the oral cavity is a multi-bacterial environment. If the implant contacts saliva during the implantation process, in the early stage of implant placement, bacterial infection may lead to implant failure.
[0003] In order to strengthen the osseointegration between the implant and the alveolar bone and improve the antibacterial effect of the implant, many methods for surface modification of implants have emerged on the market to change the chemical or physical properties of the implant surface, including changes in chemical composition or morphology, so as to improve the biocompatibility of the implant, thereby accelerating the osseointegration of the implant and improving its osseointegration efficiency, and at the same time improving its antibacterial property. At present, there are few reports on surface modification of implants using exogenous growth factors, etc., and there are problems such as high price, difficult storage, and possible antigenicity.
[0004] Therefore, it is particularly important to provide a new surface modification method for implants and modified implants. Summary of the Invention
[0005] In order to solve the above technical problems, the present application provides a surface modification method for implants and modified implants. The modified implant prepared by using the surface modification method of the present application has better biocompatibility, osseointegration ability and stronger ability to inhibit bacterial proliferation, promotes early osseointegration after implant placement, reduces the infection risk, and solves the problems such as insufficient surface activity of current implants and long osseointegration time.
[0006] In the first aspect, the present application provides a surface modification method for implants, and the surface modification method includes surface-treating the implant with a plasma matrix.
[0007] In the surface modification method provided by this application, the plasma matrix is a centrifugation product of autologous blood, which is derived from one's own blood and has good biocompatibility. At the same time, the plasma matrix contains a variety of growth factors. The growth factors may come from plasma or may be released by activated platelets. These growth factors can effectively promote cell growth and differentiation, thereby promoting osseointegration. On the other hand, the antimicrobial peptides and white blood cells contained in the plasma matrix can effectively resist the bacteria present in the oral cavity and inhibit the formation of surface biofilms, greatly improving the success rate of implants. Therefore, using the plasma matrix to modify the surface of the implant in this application can improve the surface hydrophilicity and biocompatibility of the implant, help reduce the occurrence of rejection reactions, improve the osseointegration ability and long-term survival rate of the implant, and help promote the healing and repair of surrounding tissues, improve the antibacterial property of the implant, and reduce the infection risk.
[0008] As a preferred technical solution of this application, the plasma matrix includes liquid plasma matrix, plasma matrix leachate or plasma matrix freeze-dried powder.
[0009] As a preferred technical solution of this application, the dosage of the liquid plasma matrix is 1-5 mL per implant, that is, each implant is modified with 1-5 mL of liquid plasma matrix, such as 2 mL, 3 mL, 4 mL.
[0010] As a preferred technical solution of this application, the dosage of the plasma matrix leachate is 1-5 mL per implant, that is, each implant is modified with 1-5 mL of plasma matrix leachate, such as 2 mL, 3 mL, 4 mL.
[0011] As a preferred technical solution of this application, the dosage of the plasma matrix freeze-dried powder is 50-500 mg per implant, that is, each implant is modified with 50-500 mg of plasma matrix freeze-dried powder, such as 80 mg, 100 mg, 200 mg, 300 mg, 400 mg, etc.
[0012] As a preferred technical solution of this application, the liquid plasma matrix is obtained by centrifuging blood.
[0013] In the present invention, after centrifuging the blood, it is divided into an upper liquid plasma matrix layer, a buffy coat layer and a lower red blood cell layer, and the plasma matrix is collected by a collection device, such as collected by devices such as syringes or pipettes.
[0014] As a preferred technical solution of this application, the centrifugal force for centrifugation is 50-1000 g, such as 100 g, 200 g, 300 g, 400 g, 500 g, 600 g, 700 g, 800 g, 900 g, etc., preferably 500 g, where g is the unit of centrifugal force, representing how many Gs, that is, the acceleration of gravity.
[0015] As a preferred technical solution of the present application, the centrifugation time is 2 - 10 min, such as 3 min, 4 min, 5 min, 6 min, 7 min, 8 min, 9 min, etc.
[0016] As a preferred technical solution of the present application, the plasma matrix leachate is a by - product generated by pressing the plasma matrix gel into a film. When the plasma matrix gel is pressed into a film to obtain the plasma matrix membrane, leachate will flow out, which is the plasma matrix leachate described in the present application.
[0017] As a preferred technical solution of the present application, the freeze - dried plasma matrix powder is obtained by freeze - drying liquid or solid plasma matrix.
[0018] As a preferred technical solution of the present application, the method of freeze - drying is as follows: freeze the liquid or solid plasma matrix with liquid nitrogen for 2 - 4 h, and then perform vacuum freeze - drying for 24 - 48 h, such as 28 h, 32 h, 36 h, 40 h, 44 h, etc.
[0019] As a preferred technical solution of the present application, vacuum freeze - drying is performed for 36 h, and the vacuum freeze - drying temperature is - 20 °C.
[0020] As a preferred technical solution of the present application, the method of surface treatment is to soak the implant in the liquid plasma matrix or plasma matrix leachate.
[0021] As a preferred technical solution of the present application, the soaking time is 5 - 120 min, such as 10 min, 20 min, 40 min, 60 min, 80 min, 100 min, etc.
[0022] As a preferred technical solution of the present application, the method of surface treatment is to moisten the surface of the implant with physiological saline, and then spray the freeze - dried plasma matrix powder on the surface of the implant.
[0023] The present application does not overly limit the material of the implant. The surface modification method provided by the present application is applicable to implants of various materials.
[0024] As a preferred technical solution of the present application, the material of the implant includes titanium metal, titanium alloy, bioceramics or composite materials.
[0025] In the second aspect, the present application provides a modified implant prepared by the surface modification method described in the first aspect.
[0026] By using plasma matrix to modify the surface of implants, the present application can cover the surface of implants with a large number of living cells, growth factors and protein components in autologous blood. The prepared modified implants have high surface activity and antibacterial ability, can accelerate implant osseointegration, reduce the risk of infection, and solve the problems of rejection and difficult storage in current surface biological modification of implants.
[0027] The technical solutions provided by the embodiments of the present application have the following advantages compared with the prior art:
[0028] 1. The surface modification method provided by the present application can improve the surface hydrophilicity and biocompatibility of implants, enhance the compatibility between implants and surrounding tissues, help reduce the risks of rejection reaction and foreign body reaction, and improve the osseointegration ability and long-term survival rate of implants;
[0029] 2. The surface modification method provided by the present application can promote the healing and repair of surrounding tissues after implanting the implants. The plasma matrix is rich in growth factors and cytokines, and these bioactive substances help promote the healing and repair of surrounding tissues, which is crucial for the osseointegration and early loading of implants;
[0030] 3. The surface modification method provided by the present application can improve the antibacterial performance of the implant surface, reduce the risk of infection, help reduce postoperative complications and improve the long-term stability of the implant. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The drawings here are incorporated into the specification and form a part of this specification, showing embodiments consistent with the present application, and are used together with the specification to explain the principles of the present application.
[0032] In order to more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following will briefly introduce the drawings required for the description of the embodiments or the prior art. Obviously, for those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.
[0033] Figure 1 For the alkaline phosphatase activity results on the surface of the modified titanium implant (plasma matrix) in Example 1 and the unmodified titanium implant (control);
[0034] Figure 2 For the bacterial biofilm staining maps on the surface of the modified titanium implant (plasma matrix) in Example 1 and the unmodified titanium implant (control);
[0035] Figure 3 For the SEM images of the surface of the modified titanium implant (plasma matrix) in Example 2 and the unmodified titanium implant (control) after bacterial biofilm cultivation. DETAILED DESCRIPTION OF THE EMBODIMENTS
[0036] In order to more clearly understand the above-mentioned objects, features, and advantages of the present application, the solutions of the present application will be further described below. It should be noted that, without conflict, the embodiments of the present application and the features in the embodiments can be combined with each other.
[0037] Many specific details are set forth in the following description in order to provide a thorough understanding of the present application, but the present application may also be implemented in other ways different from those described herein; obviously, the embodiments in the specification are only a part of the embodiments of the present application, rather than all of the embodiments.
[0038] Example 1
[0039] This embodiment provides a method for surface modification of an implant, including the following steps:
[0040] (1) Collect 10 mL of whole blood sample and place it in a special blood collection tube for liquid plasma matrix, quickly put it into the plasma matrix preparation platform, centrifuge for 8 min under the condition of a centrifugal force of 500 g, and collect the upper-layer liquid plasma matrix with a syringe;
[0041] (2) Inject the liquid plasma matrix into a titanium bowl, screw out the titanium implant with a carrier, and soak for 5 min;
[0042] (3) Implant the treated titanium implant into the alveolar bone socket that has been prepared according to the implant shape.
[0043] Example 2
[0044] This embodiment provides a method for surface modification of an implant, including the following steps:
[0045] (1) Collect 10 mL of whole blood sample and place it in a special blood collection tube for liquid plasma matrix, quickly put it into the plasma matrix preparation platform, centrifuge for 10 min under the condition of a centrifugal force of 300 g, and collect the upper-layer liquid plasma matrix with a syringe;
[0046] (2) Place the collected liquid plasma matrix in a sterile glass bottle, freeze it with liquid nitrogen for 2 h, and then perform vacuum freeze-drying treatment at -20 °C for 36 h to obtain plasma matrix freeze-dried powder;
[0047] (3) Moisten the surface of the titanium implant with physiological saline, and then evenly spray the plasma matrix freeze-dried powder on the surface of the titanium implant;
[0048] (4) Implant the treated titanium implant into the alveolar bone socket that has been prepared according to the implant shape.
[0049] Example 3
[0050] This embodiment provides a method for surface modification of an implant, including the following steps:
[0051] (1) Collect 10 mL of whole blood sample and place it in a special blood collection tube for liquid plasma matrix. Quickly put it into the plasma matrix preparation platform and centrifuge for 2 min under the condition of a centrifugal force of 1000 g. Use a syringe to collect the upper-layer liquid plasma matrix;
[0052] (2) Inject the liquid plasma matrix into a ceramic bowl. Spin out the bioceramic implant with a carrier and soak it for 120 min;
[0053] (3) Implant the treated bioceramic implant into the alveolar bone socket that has been prepared according to the implant morphology.
[0054] Performance Test 1
[0055] Cultivate human osteoblasts on the modified implant of Example 1 and the corresponding unmodified implant titanium surface, and perform mineralization induction for 7 days, and then detect the alkaline phosphatase activity.
[0056] The results of the alkaline phosphatase activity on the surface of the modified titanium implant (plasma matrix) of Example 1 and the unmodified titanium implant (control) are as Figure 1 shown. It can be found that the titanium surface of the implant treated with plasma matrix modification has a stronger ability to induce osteoblast differentiation and can effectively promote bone bonding.
[0057] Performance Test 2
[0058] Respectively, cultivate the surface bacterial biofilms of the modified implants of Examples 1-2 and the corresponding unmodified implants. The cultivation method is: place the implants in a bacterial culture medium and inoculate bacteria for 12 hours.
[0059] 1. Stain the bacterial biofilms on the modified titanium implant of Example 1 and the unmodified titanium implant and observe. The results are as Figure 2 shown, Figure 2 which is the staining diagram of the bacterial biofilms on the surface of the modified titanium implant (plasma matrix) of Example 1 and the unmodified titanium implant (control).
[0060] 2. Perform SEM tests on the modified titanium implant of Example 2 and the unmodified titanium implant. The results are as Figure 3 shown, Figure 3 which is the SEM diagram of the surface of the modified titanium implant (plasma matrix) of Example 2 and the unmodified titanium implant (control) after bacterial biofilm cultivation.
[0061] As can be seen from the figure, there is less bacterial growth on the surface of the implant modified with plasma matrix, and it has better antibacterial properties.
[0062] It should be noted that in this document, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the term "comprising", "including" or any other variant thereof is intended to cover non-exclusive inclusion, such that a process, method, article or device comprising a series of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such process, method, article or device. Without further limitation, an element defined by the statement "comprising an..." does not exclude the presence of additional identical elements in the process, method, article or device comprising the said element.
[0063] The above are only specific embodiments of the present application, enabling those skilled in the art to understand or implement the present application. Various modifications to these embodiments will be obvious to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to these embodiments described herein, but rather will conform to the broadest scope consistent with the principles and novel features disclosed herein.
Claims
1. A surface modification method for an implant, characterized in that, The surface modification method includes surface-treating the implant using a plasma matrix.
2. The surface modification method according to claim 1, wherein The plasma matrix includes a liquid plasma matrix, a plasma matrix leachate, or a plasma matrix freeze-dried powder.
3. The surface modification method according to claim 2, wherein The dosage of the liquid plasma matrix is 1-5 mL per implant; and / or, the dosage of the plasma matrix leachate is 1-5 mL per implant; and / or, the dosage of the plasma matrix freeze-dried powder is 50-500 mg per implant.
4. The surface modification method according to claim 2 or 3, characterized in that, The liquid plasma matrix is obtained by centrifuging blood; and / or, the plasma matrix leachate is a by-product generated by pressing a plasma matrix gel; and / or, the plasma matrix freeze-dried powder is obtained by freeze-drying a liquid or solid plasma matrix.
5. The surface modification method according to claim 4, characterized in that, The centrifugal force for the centrifugation is 50-1000 g, preferably 500 g; and / or, the centrifugation time is 2-10 min.
6. The surface modification method according to claim 4, characterized in that, The method for the freeze-drying treatment is as follows: freeze the liquid or solid plasma matrix using liquid nitrogen for 2-4 h, and then perform vacuum freeze-drying for 24-48 h; Preferably, the vacuum freeze-drying is performed for 36 h, and the vacuum freezing temperature is -20°C.
7. The surface modification method according to any one of claims 1-6, characterized in that, The method for the surface treatment is to soak the implant in the liquid plasma matrix or the plasma matrix leachate; and / or, the method for the surface treatment is to moisten the surface of the implant with physiological saline, and then spray the plasma matrix freeze-dried powder on the surface of the implant.
8. The surface modification method according to claim 7, characterized in that, The soaking time is 5-120 min.
9. The surface modification method according to any one of claims 1-8, characterized in that, The material of the implant includes titanium metal, titanium alloy, bioceramics, or composite materials.
10. A modified implant prepared by the surface modification method according to any one of claims 1-9.